Serratus Plane Block After Minimally Invasive Mitral Valve Repair

Last updated: December 12, 2022
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT05648266
19518181202119
  • Ages 18-85
  • All Genders

Study Summary

Patients undergoing minimally invasive mitral valve reconstruction via small thoracotomy are randomized into two groups.

The intervention group receives serratus anterior plane block after minimally invasive mitral-valve reconstruction, following 48h infusion with ropivacaine 2% continually.

The control group receives a placebo pump without infusion. Primary endpoints are perceived pain using a numeric pain rating scale and opioid consumption during the hospital stay.

Eligibility Criteria

Inclusion

Inclusion Criteria:

-Planned minimal invasive mitral valve repair via right anterior thoracotomy

Exclusion

Exclusion Criteria:

  • Pregenancy
  • Opioid abuse
  • Historyof chronic pain
  • Allergy to local anaesthetics (in this case ropivacain)
  • Patients who simultaneously participate in another interventional clinical trial,unless the Principal Investigators of the clinical trials give consent by mutualagreement Soft tissue infection in the area of the procedure

Study Design

Total Participants: 78
Study Start date:
April 01, 2022
Estimated Completion Date:
July 01, 2024

Connect with a study center

  • University Hospital Hamburg Eppendorf

    Hamburg, 20251
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.